MedTrace Logo

Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

NCT05376579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2026-05-19

No results posted yet for this study

Summary

This is an observational, multicenter, single-arm, prospective study conducted in Italy

Conditions

  • Active Secondary Progressive Multiple Sclerosis

Interventions

OTHER

siponimod

Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-17
Primary Completion
2025-07-22
Completion
2025-07-22

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05376579 on ClinicalTrials.gov